| Literature DB >> 31885494 |
Lyvia Lopes Miranda1, Vanessa de Paula Guimarães-Lopes2, Luciana Schulthais Altoé1, Mariáurea Matias Sarandy2, Fabiana Cristina Silveira Alves Melo2, Rômulo Dias Novaes3, Reggiani Vilela Gonçalves2.
Abstract
Bone lesions are an important public health problem, with high socioeconomic costs. Bone tissue repair is coordinated by an inflammatory dynamic process mediated by osteoprogenitor cells of the periosteum and endosteum, responsible for the formation of a new bone matrix. Studies using antioxidant products from plants for bone lesion treatment have been growing worldwide. We developed a systematic review to compile the results of works with animal models investigating the anti-inflammatory activity of plant extracts in the treatment of bone lesions and analyze the methodological quality of the studies on this subject. Studies were selected in the PubMed/MEDLINE, Scopus, and Web of Science databases according to the PRISMA statement. The research filters were constructed using three parameters: animal model, bone repair, and plant extracts. 31 full-text articles were recovered from 10 countries. Phytochemical prospecting was reported in 15 studies (48.39%). The most common secondary metabolites were flavonoids, cited in 32.26% studies (n = 10). Essential criteria to in vivo animal studies were frequently underreported, suggesting publication bias. The animals treated with plant extracts presented positive results in the osteoblastic proliferation, and consequently, this treatment accelerated osteogenic differentiation and bone callus formation, as well as bone fracture repair. Possibly, these results are associated with antioxidant, regenerative, and anti-inflammatory power of the extracts. The absence or incomplete characterization of the animal models, treatment protocols, and phytochemical and toxicity analyses impairs the internal validity of the evidence, making it difficult to determine the effectiveness and safety of plant-derived products in bone repair.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31885494 PMCID: PMC6899290 DOI: 10.1155/2019/1296153
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1PRISMA diagram. Different phases of selection of studies for conducting qualitative and quantitative analyses. Flow diagram of the systematic review literature search results. Based on “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement” (http://www.prisma-statement.org) [17].
Description of the main characteristics of the animal model in studies demonstrating the action of plant extracts in the bone repair process.
| Title | Study ID | Country | Animal model | Sex (M/F)∗ | Age (d, w, and m)∗ | Weight |
|---|---|---|---|---|---|---|
| The effect of | Chow et al., 1982 [ | China | Mice | ? | 11-12 w | 28-33 g |
| The effects of | Juma Ab, 2007 [ | Saudi Arabia | New Zealand white rabbits | ? | 6 m | 4-5 kg |
| Influence of homeopathic treatment with comfrey on bone density around titanium implants. A digital subtraction radiography study in rats | Sakakura et al., 2007 [ | Brazil | Wistar rats | M | 2 m | 180–220 g |
| The effects of phytoestrogens on fracture healing: experimental research in New Zealand white rabbits | Oztürk et al., 2008 [ | Turkey | New Zealand white rabbits | ? | ? | 1.62 ± 0.05 kg |
| Formononetin promotes early fracture healing through stimulating angiogenesis by up-regulating VEGFR-2/Flk-1 in a rat fracture model | Huh et al., 2009 [ | Korea | Sprague-Dawley rats | M | 2 m | 280-300 g |
| Equol but not genistein improves early metaphyseal fracture healing in osteoporotic rats | Kolios et al., 2009 [ | Germany | Sprague-Dawley rats | F | 3 m | ? |
| Bone regeneration potential of a soybean-based filler: experimental study in a rabbit cancellous bone defects | Giavaresi et al., 2010 [ | Italy | New Zealand white rabbits | M | Adult | 3.250 ± 0.350 kg |
| Absence of positive effect of black cohosh ( | Kolios et al., 2010 [ | Germany | Sprague-Dawley rats | F | 3 m | ? |
| Bone quality associated with daily intake of coffee: a biochemical, radiographic and histometric study | Lacerda et al., 2010 [ | Brazil | Wistar rats | ? | ? | 250-300 g |
|
| Estai et al., 2011 [ | Malaysia | Sprague-Dawley rats | F | ? | 200-250 g |
| A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action | Sharan et al., 2011 [ | India | Sprague-Dawley rats | F | ? | 200 ± 20 g |
| Evaluation of Cameroonian plants towards experimental bone regeneration | Ngueguim et al., 2012 [ | Cameroon | Sprague-Dawley rats | F | 4 m | 220 ± 20 g |
| The bone fracture-healing potential of | Kumar et al., 2013 [ | India | Wistar albino rats | F | 3 m | 150-200 g |
| Ethanol extract of | Ngueguim et al., 2013 [ | Cameroon | Sprague-Dawley rats | F | 4 m | 200 ± 20 g |
| Salvianolic acid B promotes bone formation by increasing activity of alkaline phosphatase in a rat tibia fracture model: a pilot study | He and Shen, 2014 [ | China | Sprague-Dawley rats | M | 7 w | 225 g |
|
| Neto et al., 2015 [ | Brazil | New Zealand white rabbits | M | Adult | 3.0 ± 0.5 kg |
| Repair of critical calvarias defects with systemic | Burim et al., 2016 [ | Brazil | Wistar albino rats | M | ? | 200 − 250 g |
| The effects of | Ezirganli et al., 2016 [ | Turkey | Wistar albino rats | F | 3 m | 280-310 g |
| Excavating the role of | Selvakumar et al., 2016 [ | India | New Zealand white rabbits | M | ? | 2 kg |
| Root bark of | Yang et al., 2016 [ | China | Sprague-Dawley rats | M/F | 3 m | 220 ± 20 g |
|
| Zhuang et al., 2016 [ | China | Rats | F | ? | 250-270 g |
| Dried and free flowing granules of | Adhikary et al., 2017 [ | India | Sprague-Dawley rats | F | 3 m | 180-200 g |
| Tanshinol alleviates osteoporosis and myopathy in glucocorticoid-treated rats | Chen et al., 2017 [ | China | Sprague-Dawley rats | F | 4-5 m | 250-275 g |
| Aqueous extract of | Florence et al., 2017 [ | Cameroon | Wistar rats | F | 3 m | 150-200 g |
| Heartwood extract from | Karvande et al., 2017 [ | India | Sprague-Dawley rats | F | ? | 220 ± 20 g |
| Ethanolic extract of | Khedgikar et al., 2017 [ | India | Sprague-Dawley rats | F | ? | 180 ± 20 g |
|
| Neto et al., 2017 [ | Brazil | New Zealand white rabbits | M | Adult | 3.0 ± 0.5 kg |
| Guava fruit extract and its triterpene constituents have osteoanabolic effect: stimulation of osteoblast differentiation by activation of mitochondrial respiration via the Wnt/ | Porwal et al., 2017 [ | India | Sprague-Dawley rats | F | ? | 220 ± 20 g |
|
| Giaze et al., 2018 [ | Malaysia | Sprague-Dawley rats | F | 4 m | 250-300 g |
| Grape seed extract supplement increases bone callus formation and mechanical strength: an animal study | Gurger et al., 2019 [ | Turkey | Wistar-Albino | M | 2-3 m | 350 ± 50 g |
| Extract and fraction of | Pal et al., 2019 [ | India | Sprague-Dawley rats | M | 2-3 m | 220 ± 20 g |
M: male; F: female; d: day; w: week; m: month; ?: not related.
Description of the main characteristics of the treatment in studies demonstrating the action of plant extracts in the bone repair process.
| Study ID | Number of animals/group | Control group | Treatment time (d, w, and m)∗ | Osteoporosis | Bone type | Induced defect | Lesion size | Anesthesia (pharmaco) | Postoperative drug | Euthanasia |
|---|---|---|---|---|---|---|---|---|---|---|
| Chow et al., 1982 [ | 10 | Saline | ? | No | Femur | Osteotomy | ? | Ether inhalation | ? | ? |
| Juma Ab, 2007 [ | 3 | Routine diet | 12 w | No | Femur | Drill machine | ? | Ketamine/xylazine | ? | ? |
| Sakakura et al., 2007 [ | 24 | Not receiving treatment | 28 d | No | Tibia | Rotary drills | 2 cm | Ketamine/xylazine | Pentabiótico | ? |
| Oztürk et al., 2008 [ | 11 | ? | 35 d | No | Tibia | ? | ? | Alfazin/propofol | ? | ? |
| Huh et al., 2009 [ | 144/12 | Saline | 21 d | No | Femur | ? | ? | ? | ? | Paraformaldehyde/tiletamine-zolazepam |
| Kolios et al., 2009 [ | 12 | Phytoestrogen-free | 35 d | Yes OVX | Tibia | Osteotomy | ? | Ketamine/xylazine | ? | Decapitated under deep CO2 anesthesia |
| Giavaresi et al., 2010 [ | 2/18/4 | Not receiving treatment | 24 w | No | Femur | Drill machine | 6 mm | ? | Enfloroxacin (100 mg) and metamizole chloride (50 mg/kg) | General anesthesia (Tanax) |
| Kolios et al., 2010 [ | 12 | Phytoestrogen-free | 35 d | Yes OVX | Tibia | Osteotomy | ? | Ketamine/xylazine | ? | Decapitated under deep CO2 anesthesia |
| Lacerda et al., 2010 [ | ? | Water | 7, 21, 42 d | No | Maxilla | Incisor tooth extraction | ? | 2,2,2-Tribromoethanol | Pentabiotic | Anesthetic overdose |
| Estai et al., 2011 [ | 6 | Saline | 6 w | Yes OVX | Femur | Guillotine | ? | Xylazil/ketamine | Antibiotic Baytril and povidone-iodine solution | ? |
| Sharan et al., 2011 [ | 10 | Acacia gum in water | 2 w | Yes OVX | Skull | Drill machine | 0.8 mm diameter | ? | ? | ? |
| Ngueguim et al., 2012 [ | 6 | Acacia gum in water | 12 d | No | Femur | Drill machine | 0.8 mm diameter | ? | ? | ? |
| Kumar et al., 2013 [ | 3 | Saline | 0, 7, 14, 21 d | No | Femur | Fracture device | ? | Ketamine/hydrochloride | ? | ? |
| Ngueguim et al., 2013 [ | 6 | Acacia gum in water | 12 d | No | Femur | Drill machine | 0.8 mm diameter | ? | ? | ? |
| He and Shen, 2014 [ | 10 | Saline | 12 w | No | Tibia | Custom-made three-point | ? | ? | ? | High-dose ketamine |
| Neto et al., 2015 [ | 10 | 0.9% NaCl | 10 d | No | Radius | Oscillating bone saw | 1 cm | Ketamine/xylazine | ? | Anesthetic overdose |
| Burim et al., 2016 [ | 20 | Saline | 7, 14, 21, 42 d | No | Calvaria | Steel trephine drill | 8 mm diameter | Ketamine/xylazine/hydrochloride | Antibiotic prophylaxis (benzathine benzylpenicillin) | CO2 chamber |
| Ezirganli et al., 2016 [ | 16 | ? | 2, 4 w | Yes OVX | Calvaria | Trephine burr | 5 mm diameter | Ketamine/xylazine | ? | Barbiturate overdose |
| Selvakumar et al., 2016 [ | ? | ? | 4 w | No | Tibia | Drill machine | 4 mm | Ketamine/xylazine | Meloxicam oral suspension (0.2 mg/kg) and enrofloxacin (5 mg/kg) | ? |
| Yang et al., 2016 [ | 24 | Water | 2, 4, 8 w | No | Femur | Osteotomy | ? | Chloral hydrate | Penicillin sodium | ? |
| Zhuang et al., 2016 [ | 8 | Methylcellulose | 14 d | No | Femur | Drill machine | 0.8 mm diameter | Ketamine/xylazine | ? | ? |
| Adhikary et al., 2017 [ | 10 | Parathyroid hormone (PTH) | 14 d | ? | Femur | Drill machine | 0.8 mm diameter | ? | ? | ? |
| Chen et al., 2017 [ | 24 or 16 | Water/calcitriol | 6 w | Yes GIOP | Tibia | ? | 2 mm hole | Chloral hydrate | ? | Cardiac puncture |
| Florence et al., 2017 [ | 5 | Water | 14 d | No | Femur | Drill machine | ? | ? | ? | Decapitated under ketamine/valium anesthesia |
| Karvande et al., 2017 [ | 10 | Acacia gum in water | 2 w | No | Femur | Drill machine | 0.8 mm diameter | Ketamine/xylazine | ? | ? |
| Khedgikar et al., 2017 [ | ? | Acacia gum in water | 2 w | No | Femur | Drill machine | 0.8 mm diameter | ? | ? | ? |
| Neto et al., 2017 [ | 12 | Not receiving treatment | 10 d | No | Radius | Oscillating bone saw | 1 cm | Ketamine/xylazine | ? | Lethal doses of the anesthetics |
| Porwal et al., 2017 [ | ? | Water | 12 d | No | Femur | Drill machine | 0.8 mm diameter | Ketamine/xylazine | ? | ? |
| Giaze et al., 2018 [ | 6 | Estrogen (Premarin®) | 4 m | Yes | Tibia | Pulse ultrasound | 0.5 mm | Ketamine/xylazine | Enrofloxacin (Baytril®) 5 mg/kg and buprenorphine 0.1 mg/kg | Ketamine-xylazine mixture overdose and cervical dislocation |
| Gurger et al., 2019 [ | 8 | Standard diet | 10, 20, and 30 d | No | Femur | Multidrilling technique | 0.5cm | Ketamine/xylazine | Buprenorphine (0.05 mg/kg) and cefazolin (30 mg/kg) | Sodium pentobarbital (400 mg/kg) |
| Pal et al., 2019 [ | 10 | Water | 14 w | Yes GIO | Femur | Drill machine | 0.8 mm | Ketamine/xylazine | ? | Ketamine/xylazine overdose |
d: day; w: week; m: month; OVX: ovariectomized; GIOP: Glucocorticoid-Induced Osteoporosis Program; GIO: GC-induced osteoporosis; ?: not related.
Main characteristics of the plant, extraction form, route, and dose administered in studies demonstrating the action of plant extracts in the bone repair process.
| Study ID | Plant | Used parts | Indication | Solvent used for extraction | Obtaining plant material | Dose | Administration | Secondary metabolites | Geographic distribution |
|---|---|---|---|---|---|---|---|---|---|
| Selvakumar et al., 2016 [ |
| Leaves | Anti-inflammatory, antioxidant activity, immune modulatory, and burn wounds | Water | ? | ? | Grafts | Saponins | ? |
| Huh et al., 2009 [ |
| Root | Vascular diseases, breast cancer, climacteric bone diseases (reports) | Water/ethanol | Seoul, Korea | 20 | Orally, | Isoflavone formononetin | ? |
| Pal et al., 2019 [ |
| Stem and leaves | Purgative, febrifuge, diuretic, and treatment of fracture and bone diseases | Ethanol | Lucknow, India | 250 mg/kg and 100 mg/kg | Orally, | Flavonoids | South Asia and South America |
| Neto et al., 2015 [ |
| Leaves | Contusions and fractures | Water | Brazil | 10 mL | Topical | ? | Brazil and Latin America |
| Neto et al., 2017 [ |
| Leaves | Inflammatory conditions, contusions, and fractures | Water | Brazil | 20 g | Grafts | Flavonoids, alkaloids, and saponins | Brazil and Latin America |
| Kolios et al., 2010 [ |
| Rhizomes | Reduce climacteric complaints (proven) | Water/ethanol | ? | 24.9 mg/day | Orally, | ? | ? |
| Lacerda et al., 2010 [ | Coffee | ? | Protein expression of the vitamin D receptor, osteoblast activity, anti-inflammatory (reports) | Water | SP, Brazil | 50 mg/mL | Orally, | Caffeine (reports) | ? |
| Sakakura et al., 2007 [ | Comfrey ( | ? | Fractured bone, tendon damage, joint disease, and ulcerations in the gastrointestinal tract | Ethanol | ? | 6CH (homeopathic dose) | Grafts | ? | ? |
| Karvande et al., 2017 [ |
| Heartwood | Stimulation of new cell growth, tissue regeneration (reports) | Ethanol | Lucknow, India | 250, 500, and 1000 mg/kg/day | ? | Neoflavonoids (reports) | Indian subcontinent |
| Khedgikar et al., 2017 [ |
| Leaves | Stimulation of new bone cells, tissue regeneration, anti-inflammatory (reports) | Ethanol | Lucknow, India | 250, 500, and 1000 mg/kg/day | Orally, | Phytoestrogens, flavonoids (reports) | Indian subcontinent |
| Chow et al., 1982 [ |
| ? | Fractures (traditional uses) | Methanol | ? | 10 mg/kg or 30 mg/kg | Intraperitoneal | ? | ? |
| Ngueguim et al., 2012 [ |
| Leaves, twigs, or whole plant | Bone diseases and fracture repair, anti-inflammatory (traditional uses) | Ethanol | Dschang region, Cameroon | 250, 500, and 750 mg/kg | Orally, | ? | ? |
| Burim et al., 2016 [ |
| Dried leaves | Bone repair, osteoporosis, anti-inflammatory (reports) | Water/ethanol | Shaanxi, China | 0.3 mL | Gavage | Flavonoid icariin | Asian countries |
| Gurger et al., 2019 [ | Grape seed | Seed | Vasodilator, antiallergic, immunostimulator, anti-inflammatory, cardioprotective, antiviral, antibacterial, and anticarcinogen activities | 1% carboxymethyl cellulose | United States of America | 100 mg/kg/day | Gavage | ? | ? |
| Juma Ab, 2007 [ |
| Seeds | Diuresis, bile function, cough, fracture healing, anti-inflammatory (traditional uses) | ? | Saudi Arabia | 6 g/day | Orally, | ? | ? |
| Giaze et al., 2018 [ |
| Leaves and roots | Reproductive health problems and postmenopausal symptoms, known to protect the bone against osteoporosis | Water | Malaysia | 20 and 100 mg/kg/day | Orally, | Phenolic compounds | ? |
| Ezirganli et al., 2016 [ |
| Seed | Analgesic, antipyretic, anti-inflammatory, antimicrobial, antibacterial, antifungal, antiparasitic, antiasthmatic, antioxidant, antineoplastic | ? | ? | 10 mg/kg/day | Gavage | Proteins, alkaloids, essential oils, saponin | ? |
| Kumar et al., 2013 [ |
| Leaves | Fractures (traditional uses) | Methanol | Kancheepuram district, Tamil Nadu, India | 100 mg/kg−1 | Topical/orally, | ? | Jungles of the Coromandel coast and dry forest from Tamil Nadu, India |
| Ngueguim et al., 2013 [ |
| Whole plant | Fractures, abdominal pain, headache, hypertension, anti-inflammatory (traditional uses) | Ethanol | Dschang region, Cameroon | 100 and 200 mg/kg | Orally, | ? | Damp areas from Cameroon |
| Florence et al., 2017 [ |
| Whole plant | Abdominal pain, anti-inflammatory, boils, colic, fatigue, gout, rheumatic, joint pain, fracture management (traditional uses) | Water | Limbe, Cameroon | 100, 200, and 400 mg/kg | Orally, | Flavonoids (reports) | America, Africa, and Asia |
| Estai et al., 2011 [ |
| Leaves | Diabetes, hypertension, and joint aches (traditional uses) | ? | ? | 125 mg/kg/day | Orally, | Alkaloids, amides, flavonoids, lignans, phenylpropanoids (reports) | ? |
| Porwal et al., 2017 [ |
| Fruits | Diabetes, obesity, osteoporosis (traditional uses) | Ethanol | Sitapur, Uttar Pradesh, India | 250 mg/kg | ? | Polyphenols, carotenoids (reports) | ? |
| Chen et al., 2017 [ |
| ? | Osteoporosis, osteogenesis, anti-inflammatory (reports) | ? | ? | 25 and 50 mg/kg | Gavage | Tanshinol | ? |
| Yang et al., 2016 [ |
| Root bark | Fractures, anti-inflammatory, osteoporosis (traditional uses) | Ethanol | Harbin, China | 340 and 680 mg/kg | Orally, | Lignans, iridoids | China |
| Kolios et al., 2009 [ | Soybeans | ? | Osteoporosis (reports) | ? | ? | 1 g/kg | Orally, | Isoflavone genistein | ? |
| Giavaresi et al., 2010 [ | Soybean | ? | ? | Water/ethanol | ? | ? | Grafts | Isoflavones, phytoestrogens | ? |
| Adhikary et al., 2017 [ |
| Whole plant | Increased satiety in females and lipid-lowering effects in postmenopausal women (previous reports) | Ethanol | ? | 125, 250, 500, and 750 mg/kg/day | Orally, | Ascorbate, carotenoids, tocopherols, phenolics, flavonoids, folate | ? |
| Zhuang et al., 2016 [ |
| Stem bark | Anti-inflammation, edema, stomach cancer (traditional uses) | Ethanol | ? | 50, 100, 250, and 500 mg/kg | Gavage | Flavonoids (catechin) | Korean Peninsula |
| Sharan et al., 2011 [ |
| Stem bark | Fractures (traditional uses) | Ethanol | ? | 1.0 mg/kg/day and 5.0 mg/kg/day | Orally, | Flavonoid quercetin | ? |
| Oztürk et al., 2008 [ |
| Fruits | Bone loss and resorption, heart disease (reports) | Ethanol | ? | 0.75 mg | Intramuscular | Flavonoids (reports) | Middle East and Southern Europe |
?: not related; CH: diluted 100×.
Figure 2Main results of the studies demonstrating the action of plant extracts in the bone repair process.
Figure 3Analysis of methodological bias (reporting quality) for each study included in the review. Based on Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (http://www.nc3rs.org.uk/arrive-guidelines). The dotted line indicated the mean quality score (%). Detailed bias analysis stratified by domains and items evaluated is presented in Supplementary Material 1.
Analysis of methodological bias of the studies demonstrating the action of plant extracts in the bone repair process.
| Chow et al., 1982 [ | Juma Ab, 2007 [ | Sakakura et al., 2007 [ | Oztürk et al., 2008 [ | Huh et al., 2009 [ | Kolios et al., 2009 [ | Giavaresi et al., 2010 [ | Kolios et al., 2010 [ | Lacerda et al., 2010 [ | Estai et al., 2011 [ | Sharan et al., 2011 [ | Ngueguim et al., 2012 [ | Kumar et al., 2013 [ | Ngueguim et al., 2013 [ | He and Shen, 2014 [ | Neto et al., 2015 [ | Burim et al., 2016 [ | Ezirganli et al., 2016 [ | Selvakumar et al., 2016 [ | Yang et al., 2016 [ | Zhuang et al., 2016 [ | Adhikary et al., 2017 [ | Chen et al., 2017 [ | Florence et al., 2017 [ | Karvande et al., 2017 [ | Khedgikar et al., 2017 [ | Neto et al., 2017 [ | Porwal et al., 2017 [ | Giaze et al., 2018 [ | Gurger et al., 2019 [ | Pal et al., 2019 [ | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Title | |||||||||||||||||||||||||||||||||
| Accurate and concise description of the article content | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 29 | 93.55% | ||
|
| |||||||||||||||||||||||||||||||||
| Abstract | |||||||||||||||||||||||||||||||||
| Background summary, research objectives, methods, principal findings, and conclusions | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 24 | 77.42% | |||||||
|
| |||||||||||||||||||||||||||||||||
| Introduction | |||||||||||||||||||||||||||||||||
| Sufficient scientific background | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 30 | 96.77% | |
| Explanation of the experimental approach and rationale | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 31 | 100% |
|
| |||||||||||||||||||||||||||||||||
| Objectives | |||||||||||||||||||||||||||||||||
| Clear primary and second objectives | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 24 | 77.42% | |||||||
|
| |||||||||||||||||||||||||||||||||
| Materials and methods | |||||||||||||||||||||||||||||||||
| Nature of the ethical review permissions, relevant licenses, and national or institutional guidelines for the care and use of animals | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 25 | 80.64% | ||||||
|
| |||||||||||||||||||||||||||||||||
| Number of animals per group | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 26 | 83.87% | |||||
| Information on whether the experiment was performed as a blind controlled study | X | X | X | X | X | X | X | X | X | X | 10 | 32.26% | |||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Treatment description | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 28 | 90.32% | |||
| Treatment dosage | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 29 | 93.55% | ||
| Treatment duration | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 30 | 96.77% | |
| Time of day of treatment administration | X | X | 2 | 6.45% | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Information regarding animal species | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 31 | 100% |
| Animals' strain | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 29 | 93.55% | ||
| Animals' sex | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 27 | 87.09% | ||||
| Animals' weight range | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 30 | 96.77% | |
| Animals' age | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 19 | 61.29% | ||||||||||||
| Description of genetic modification status (knockout, transgenic, SPF) | 0 | 0% | |||||||||||||||||||||||||||||||
| Information related to previous procedures performed on the animals | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 14 | 45.16% | |||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Housing of experimental animals (facility type, cage or housing type, material, number of cage companions) | X | X | X | X | X | X | X | X | X | 9 | 29.03% | ||||||||||||||||||||||
| Husbandry conditions (breeding program, light/dark cycle, temperature, water) | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 15 | 48.39% | ||||||||||||||||
| Welfare-related assessments and interventions that were carried out before, during, or after the experiment | X | X | X | X | X | X | X | X | X | X | 10 | 32.26% | |||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Total number of animals used in each experimental group and the number of animals in each experimental group | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 23 | 74.19% | ||||||||
| Explanation regarding the decision of the number of animals and details of sample size calculation | X | 1 | 3.22% | ||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Full details of how animals were allocated to experimental groups (including randomization or matching) | X | X | X | X | X | X | X | X | X | 9 | 29.03% | ||||||||||||||||||||||
| Order in which the animals in the different experimental groups were treated and assessed | 0 | 0% | |||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Clear experimental outcomes assessed | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 28 | 90.32% | |||
|
| |||||||||||||||||||||||||||||||||
| Statistical methods used for each analysis | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 28 | 90.32% | |||
| Unit of analysis specifications for each dataset | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 27 | 87.09% | ||||
| Methods used to assess whether the data met the assumptions of the statistical approach | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 28 | 90.32% | |||
|
| |||||||||||||||||||||||||||||||||
| Results | |||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Description of animals' health status, for each experimental group, before treatment | 0 | 0% | |||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Number of animals in each group included in each analysis (absolute numbers) | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 29 | 93.55% | ||
| Animals or data not included in the analysis (and explanation for the exclusion) | X | X | 2 | 6.45% | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Information (mean = standard deviation) | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 28 | 90.32% | |||
|
| |||||||||||||||||||||||||||||||||
| Information regarding mortality of experimental animals (mean = standard deviation) | X | X | 2 | 6.45% | |||||||||||||||||||||||||||||
| Modifications to the experimental protocols made to reduce adverse events | 0 | 0% | |||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Discussion | |||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Interpretation of the results, taking into account the study objectives and hypotheses, current theory, and relevant studies | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 31 | 100% |
| Comments on the study limitations (sources of bias, limitations of the animal model, imprecision associated with the results) | X | X | X | X | X | X | 6 | 19.35% | |||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| Comments on how the findings are likely to translate to other species or systems, including relevance to human biology | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 14 | 45.16% | |||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
| List of funding sources and the role of the funder(s) in the study | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 14 | 45.16% | |||||||||||||||||
| Total results | 14 | 21 | 25 | 22 | 30 | 25 | 22 | 25 | 22 | 26 | 24 | 25 | 18 | 25 | 27 | 26 | 31 | 23 | 22 | 24 | 22 | 26 | 26 | 25 | 30 | 24 | 23 | 23 | 25 | 24 | 20 | ||
X: related; unmarked: not related.